Cytokine Production and NET Formation by Monosodium Urate-Activated Human Neutrophils Involves Early and Late Events, and Requires Upstream TAK1 and Syk.


Journal

Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960

Informations de publication

Date de publication:
2019
Historique:
received: 06 07 2019
accepted: 05 12 2019
entrez: 4 2 2020
pubmed: 6 2 2020
medline: 15 12 2020
Statut: epublish

Résumé

Gout is a prevalent and incapacitating disease triggered by the deposition of monosodium urate (MSU) crystals in joints, which are also massively infiltrated by neutrophils. The interaction of the latter with MSU crystals triggers several responses, including the generation of inflammatory mediators and of neutrophil extracellular traps (NETs). Though some of the signaling events mobilized by MSU in neutrophils have been described (e.g., Src family kinases, Syk, PKC, PI3K), the picture remains fragmentary. Likewise, the impact of these signaling events on cellular responses is incompletely understood. In this study, we examined transcriptomic changes triggered by MSU in neutrophils and their impact on the corresponding proteins, as well as the role of various signaling pathways in prominent functional responses. We report for the first time that neutrophils can secrete the monocyte chemoattractant, CCL4, in response to MSU. Accordingly, we found that transcription factors NF-κB, CREB, and C/EBP are belatedly activated by MSU crystals, and at least the former is involved in chemokine generation. Moreover, we show that MAPKs and Akt are activated by MSU in neutrophils, that they are under the control of TAK1 and Syk, and that they participate in cytokine generation and NETosis. In the latter instance, we found the phenomenon to be independent of endogenous ROS, but under the control of PAD4. We finally provide evidence that endogenous factors contribute to the belated phosphorylation of kinases and transcription factors in response to MSU. Collectively, our findings unveil potentially important therapeutic targets for gouty arthritis.

Identifiants

pubmed: 32010124
doi: 10.3389/fimmu.2019.02996
pmc: PMC6974451
doi:

Substances chimiques

Cytokines 0
Uric Acid 268B43MJ25
Syk Kinase EC 2.7.10.2
MAP Kinase Kinase Kinases EC 2.7.11.25
MAP kinase kinase kinase 7 EC 2.7.11.25

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

2996

Subventions

Organisme : CIHR
Pays : Canada

Informations de copyright

Copyright © 2020 Tatsiy, Mayer, de Carvalho Oliveira, Sylvain-Prévost, Isabel, Dubois and McDonald.

Références

Front Immunol. 2012 Sep 03;3:277
pubmed: 22969769
Front Immunol. 2018 Sep 18;9:2036
pubmed: 30279690
Rheumatol Int. 1997;16(6):231-5
pubmed: 9106933
Ann Rheum Dis. 2009 Oct;68(10):1602-8
pubmed: 19528034
J Exp Med. 1995 Dec 1;182(6):2019-25
pubmed: 7500047
J Immunol. 1990 Apr 1;144(7):2719-24
pubmed: 2108211
Science. 2004 Mar 5;303(5663):1532-5
pubmed: 15001782
J Leukoc Biol. 2001 Dec;70(6):961-8
pubmed: 11739559
Drugs. 2018 Jun;78(9):959-963
pubmed: 29869203
Arthritis Rheum. 1977 Nov-Dec;20(8):1538-42
pubmed: 921826
PLoS One. 2011;6(12):e29318
pubmed: 22195044
PLoS One. 2018 Feb 6;13(2):e0192464
pubmed: 29408858
BMC Immunol. 2008 Apr 11;9:14
pubmed: 18405381
J Immunol. 2010 Apr 1;184(7):3897-906
pubmed: 20200282
J Immunol. 2018 Mar 1;200(5):1802-1816
pubmed: 29367211
Clin Biochem. 1988 Dec;21(6):341-5
pubmed: 3233746
Arthritis Rheum. 2000 May;43(5):1145-55
pubmed: 10817569
J Immunol. 2005 Aug 1;175(3):1834-42
pubmed: 16034126
Blood. 1995 Nov 1;86(9):3567-74
pubmed: 7579465
Arthritis Rheum. 1968 Apr;11(2):145-50
pubmed: 5645727
Clin Cancer Res. 2016 Mar 1;22(5):1095-102
pubmed: 26581242
Blood. 1997 May 1;89(9):3421-33
pubmed: 9129050
FASEB J. 2009 Jan;23(1):194-203
pubmed: 18780764
J Leukoc Biol. 2015 Oct;98(4):565-73
pubmed: 26243391
J Immunol. 2013 Oct 15;191(8):4299-307
pubmed: 24038085
J Immunol. 2015 Dec 1;195(11):5393-403
pubmed: 26491199
Agents Actions. 1991 Sep;34(1-2):38-41
pubmed: 1793049
J Immunol. 1994 Jun 1;152(11):5485-94
pubmed: 8189066
Eur J Immunol. 2011 Jun;41(6):1709-19
pubmed: 21469098
J Leukoc Biol. 2013 Oct;94(4):693-703
pubmed: 23401599
J Leukoc Biol. 2001 Oct;70(4):659-68
pubmed: 11590204
J Leukoc Biol. 2004 Aug;76(2):433-40
pubmed: 15107458
J Immunol. 2009 Jan 1;182(1):563-71
pubmed: 19109189
J Leukoc Biol. 2007 Feb;81(2):567-77
pubmed: 17062602
J Leukoc Biol. 2017 Sep;102(3):805-813
pubmed: 28550118
Curr Rheumatol Rep. 2008 Jul;10(3):218-27
pubmed: 18638431
J Rheumatol. 2006 May;33(5):928-38
pubmed: 16652423
J Immunol Res. 2017;2017:4347121
pubmed: 28512645
J Leukoc Biol. 2007 Sep;82(3):763-73
pubmed: 17535983
Sci Rep. 2017 Nov 3;7(1):15003
pubmed: 29101355
Arthritis Rheum. 1993 Jan;36(1):117-25
pubmed: 8381010
Crit Rev Clin Lab Sci. 2002 Feb;39(1):63-88
pubmed: 11890208
Prostaglandins. 1984 Apr;27(4):563-81
pubmed: 6328582
Expert Opin Investig Drugs. 2018 Jan;27(1):17-30
pubmed: 29216787
J Immunol. 2016 May 1;196(9):3686-94
pubmed: 27016607
J Immunol. 2000 Nov 15;165(10):5798-806
pubmed: 11067939
J Immunol. 2009 Aug 1;183(3):2104-14
pubmed: 19596988
Arthritis Rheum. 1982 Feb;25(2):174-80
pubmed: 6279115
J Exp Med. 1966 Jul 1;124(1):115-26
pubmed: 5944345
Sci Rep. 2017 Jul 26;7(1):6529
pubmed: 28747804
Eur J Immunol. 2016 Jan;46(1):223-9
pubmed: 26531064

Auteurs

Olga Tatsiy (O)

Pulmonary Division, Faculty of Medicine, Université de Sherbrooke and Centre de recherche du CHUS (CRCHUS), Sherbrooke, QC, Canada.
Department of Immunology and Cell Biology, Faculty of Medicine, Université de Sherbrooke and CRCHUS, Sherbrooke, QC, Canada.

Thomas Z Mayer (TZ)

Pulmonary Division, Faculty of Medicine, Université de Sherbrooke and Centre de recherche du CHUS (CRCHUS), Sherbrooke, QC, Canada.
Department of Immunology and Cell Biology, Faculty of Medicine, Université de Sherbrooke and CRCHUS, Sherbrooke, QC, Canada.

Vanessa de Carvalho Oliveira (V)

Pulmonary Division, Faculty of Medicine, Université de Sherbrooke and Centre de recherche du CHUS (CRCHUS), Sherbrooke, QC, Canada.
Department of Immunology and Cell Biology, Faculty of Medicine, Université de Sherbrooke and CRCHUS, Sherbrooke, QC, Canada.

Stéphanie Sylvain-Prévost (S)

Pulmonary Division, Faculty of Medicine, Université de Sherbrooke and Centre de recherche du CHUS (CRCHUS), Sherbrooke, QC, Canada.

Marilyn Isabel (M)

Pulmonary Division, Faculty of Medicine, Université de Sherbrooke and Centre de recherche du CHUS (CRCHUS), Sherbrooke, QC, Canada.

Claire M Dubois (CM)

Department of Immunology and Cell Biology, Faculty of Medicine, Université de Sherbrooke and CRCHUS, Sherbrooke, QC, Canada.

Patrick P McDonald (PP)

Pulmonary Division, Faculty of Medicine, Université de Sherbrooke and Centre de recherche du CHUS (CRCHUS), Sherbrooke, QC, Canada.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH